Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Fluctuating Capacity and Demand Conditions in Biomanufacturing
Author(s)Randi Hernandez
BioPharm International eBooks
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Contract manufacturing is a booming business, especially considering that many pharmaceutical companies-including those with a focus on biologic products- are no longer conducting much of their own research and development in-house. Fewer still are capable of scaling up from laboratory to commercial production without some type of outside help from a contract manufacturing organization (CMO). Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
about 11 years ago
Cleaning Validation for Biologicsabout 11 years ago
Automation of Single-Use Systemsabout 11 years ago
Are Biopharma Patents Poised on the Post-Grant Chopping Block?about 11 years ago
Raising the Bar for Biopharma TrainingAdvertisement
Related to this article
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5